According to filings with the U.S. Securities and Exchange Commission, HistoSonics is raising $85,000,000.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Mike Blue played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About HistoSonics
HistoSonics is a venture-backed medical device start-up company developing a non-invasive sonic beam therapy platform and procedure using the science of histotripsy. Histotripsy utilizes the pressure created by focused sound energy to liquify and destroy targeted tissue, including diseased tissue and tumors, at sub-cellular levels. The companys new platform deliverers personalized, tissue specific treatments with precision and control, and without the undesirable side effects of many of todays interventional and surgical modalities. HistoSonics is led by a team of experienced domain experts and industry leaders with offices in Ann Arbor, Michigan and Minneapolis, MN.

To learn more about HistoSonics, visit http://www.histosonics.com/

Contact:
Mike Blue, President and Chief Executive Officer
734-926-4633
https://www.linkedin.com/in/mike-blue-860b9522/

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved